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Human natural killer (NK) cells are functionally regulated by killer cell immunoglobulin-like
receptors (KIRs) and their interactions with HLA class I molecules. As KIR expression in a
given NK cell is stochastically established, KIR repertoire perturbations reflect a dominance
of discrete NK-cell subsets as the consequence of adaptation of the NK-cell compartment
to exogenous agents, more often represented by virus infection. Although inhibitory inter-
actions between KIR and their cognate HLA class I ligands abrogate effector responses of
NK cells, they are also required for the functional education of NK cell.The biology and mol-
ecular specificities of the activating KIRs are less well defined, and most interactions with
presumed HLA class I ligands are weak. Interestingly, epidemiologic studies link activating
KIR genes to resistance against numerous virus infections. Chronic lymphoproliferative
disorder of NK cells (CLPD-NK) is an indolent NK cell disease characterized by a persistent
increase of circulating NK cells (usually exceeding 500 NK cells/mm3). The mechanism
through which NK cells are induced to proliferate during CLPD-NK pathogenesis is still a
matter of debate. Accumulating data suggest that exogenous agents, in particular viruses,
might play a role. The etiology of CLPD-NK, however, is largely unknown. This is likely due
to the fact that not a single, specific agent is responsible for the NK cells proliferation,
which perhaps represents the expression of an abnormal processing of different foreign
antigens, sharing a chronic inflammatory background. Interestingly, proliferating NK cells
are typically characterized by expression of a restricted pattern of KIR, which have been
demonstrated to be mostly represented by the activating form. This finding indicates that
these receptors may be directly involved in the priming of NK cells proliferation.
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INTRODUCTION
The chronic lymphoproliferative disorders of NK cells (CLPD-
NK) are included among the novelties of the current World
Health Organization (WHO) classification (1). These rare and
heterogeneous disorders are characterized by a chronic expan-
sion of mature appearing NK cells (usually more than 500/µl)
in peripheral blood for more than 6 months (2–6), without a
clearly identified cause (Figure 1). Patients are usually adults with
a mean age of 60 years without gender and racial predisposition
(7). The circulating cells show typical large granular lymphocyte
(LGL) morphology, with moderate amount of pale cytoplasm that
contains ≥3 azurophilic granules. Bone marrow biopsy is char-
acterized by interstitial infiltration of cells with small nuclei and
pale cytoplasm, which are difficult to recognize without the help of
immunohistochemical techniques. Pathological NK cells express
CD16 and usually low levels of CD56 and CD57. As expected, cells
express T-cell intracellular antigen 1 (TIA1), granzyme and per-
forins, which correlate with the cytotoxic potential of these cells
displayed in vitro cytotoxic assays. CD94 antigen is expressed at
high density on patients’ NK cells; this antigen is usually associ-
ated with the inhibitory subunit NKG2A, although in a relevant
number of cases the association CD94/NKG2C has been reported
(8). Patients’ NK cells characteristically express functional β and γ
chains of IL-2/IL-15 receptor, which are strictly related to the role
of these cytokines in the pathogenesis of disease (9). Cytogenetic is
normal in most cases (9) and the germ line configuration of TCR is
usually demonstrated, as expected for normal NK cells. Since clon-
ality of proliferating cells is difficult to detect in these patients, the
analysis of restriction fragment length polymorphism (RFLP) has
been used as marker to demonstrate the clonality in some but not
all patients. The evidence of a restricted pattern of clonally dis-
tributed KIR genes expression by proliferating NK cells might also
provide indirect demonstration of clonality (10). In rare case in
which EBV can be demonstrated in plasmid form within NK cells,
the clonality of cells might be easily examined by Southern Blot
analysis using probes recognizing the EBV terminal repeats (11).
Most patients are asymptomatic, and the disease has a chronic
indolent clinical course, similar to that reported for patients with
T-LGL leukemia (T-LGLL) (2–6); in these cases, the disease is diag-
nosed by blood analysis performed for other purposes. In some
cases, this disorder is associated with other conditions, including
pure red cell aplasia, vasculitic syndromes, solid and hematologic
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FIGURE 1 |Typical large granular lymphocyte morphology as detected
in a CLPD-NK patient.
tumors, splenectomy, neuropathy, and autoimmune disorders (2–
6). Recently in patients with chronic myelogenous leukemia, the
association has been reported between treatment with dasatinib
and the development of CLPD-NK. It has been suggested that
the development of CLPD-NK might have a therapeutic effect
on Ph positive leukemic cells (12). Systemic symptoms, such
as cytopenia (mostly neutropenia and anemia), are uncommon.
Lymphadenopathy, hepatomegaly, splenomegaly, and cutaneous
lesions are uncommon. Occasionally,patients present with a slowly
progressive increase of peripheral blood NK cells and with organ
involvement. In rare cases, the disease transforms to aggressive NK
cell leukemia (13). These EBV positive patients usually suffer from
chronic active EBV infection and should carefully be monitored
for the emergence of clonal cells (11). Several cases with a sponta-
neous complete remission have been reported (14). Patients with
CLPD-NK usually have an indolent clinical course and respond to
immunosuppressive therapy with low doses of methotrexate (usu-
ally 10 mg/m2/week) or cyclophosphamide (50 or 100 mg/day) or
cyclosporin (3–5 mg/kg/day) with or without inclusion of low
doses of steroid (15). Because of the potential long-term side
effects of immunosuppressive therapy, limiting specific therapy
only to patients with symptomatic disease is recommended.
CLPD-NK EXPRESS ACTIVATING KIR
In recent years, several studies have been published focusing on
the pathogenetic mechanisms of this disease (9, 16–20). A genetic
susceptibility for this disease has been suggested and has been
related to the detection in these patients of type B KIR gene reper-
toire, which is characterized by a high number of activating genes
(21). As indicated above, a restricted pattern of KIR expression
has usually been reported in these patients, which is characterized
either by a dominant expression of a relevant KIR, or by a lack of
KIR expression (22). A typical feature of these patients is the pref-
erential expression of the KIR activating receptors isoforms (10,
23). Together with a bias toward activating KIR expression, a deep
silencing of inhibitory KIR through increased gene methylation
has been demonstrated by our group (19). More specifically, we
showed the complete lack of KIR3DL1 expression in most ana-
lyzed patients, being the receptor expressed in 13% of patients as
compared to 90% of controls (p< 0.01). Interestingly, the results
of methylation patterns of KIR3DL1 promoter showed a signifi-
cantly higher methylation status (0.76± 0.12 SD) in the patients
with respect to the healthy subjects (0.49± 0.10 SD, p< 0.01).
These data suggest that together with the increased expression of
activating receptors, the lack of the inhibitory signal could also
play a role in the pathogenesis of disease (19). Only few studies
addressed the expression of NCR, NKG2D, and other activating
receptors. We investigated the expression of these receptors in a
series of 18 cases of LDGL patients and showed that, among NCR
antigen expression, NKp30 was strongly down regulated in all but
one of the cases analyzed. Similarly the NKp46 receptor in most
instances was detected only in small fractions of NK cells (10).
These peculiar phenotypic results in these patients suggested the
occurrence of a defect in NCR expression that was reminiscent of
that reported in acute myeloid leukemia patients (24). Regarding
NKp44, which is normally expressed only in activated NK cells,
this receptor was not expressed at significant levels on LGL sur-
face of the patients analyzed. A completely different pattern was
observed for NKG2D, NKp80, and 2B4 molecules that were homo-
geneously present on NK cells in the majority of the patients. All
together, these data indicate that in most cases patients’ NK cells
express normal levels of NKG2D while NCR molecules are gener-
ally present at low density. In addition, although in most patients
NK cells were characterized by the CD94/NKG2A+ phenotype, a
minor fraction of cases (nearly 20%) expressed CD94+/NKG2C+
phenotype (10).
CLPD-NK AND VIRAL INFECTIONS
Natural killer cell activation in response to an unknown stim-
ulus, likely of viral origin, is postulated to play a role in the
initial steps of CLPD-NK by selecting NK clones (Figure 2) (25).
Although no prototypical HTLV infection was demonstrated in
these patients, the evidence that in 73% of cases sera from a series
of patients from Europe and USA reacted with the recombinant
HTLV env protein p21E suggests that exposure to a protein con-
taining homology to BA21 may be important in the pathogenesis
of this lymphoproliferative disorder (16, 26).
In contrast with other mature NK cell neoplasms, EBV DNA
is not usually detected within affected lymphocytes in USA and
Europe countries (27) (6/16 NK LGL positive for EBV DNA),
whereas a significative high incidence has been reported in Japan-
ese patients, usually correlating with a more aggressive clinical
behavior (11). Anyway the link between EBV infection and LGL
disease is sustained by the observation that spontaneous resolution
of KIR restricted LGL associated with disappearance of EBV DNA
(28). Among Herpes viruses, Human CMV has been reported to
be crucial in influencing NK receptor expression in NK cells (29).
Remarkably, elevated numbers of CD94/NKG2C+ NK cells, pre-
viously shown to expand in association to CMV infection (30),
were preferentially found in Vbeta13.1+ CD4+ T-LGLL, further
supporting its role in the pathogenesis of a subset of T-LGLL (31).
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FIGURE 2 | Hypothetical pathogenic events leading to CLPD-NK. A
stimulation by exogenous antigen(s), such as virus, represents the initial
stimulus inducing the activation and clonal expansion of NK cells, selecting
preferentially NK cells equipped with activating KIR, probably because these
NK cells are more responsive. LGL expansion at the beginning could be
polyclonal but then it becomes monoclonal and chronic, sustained by the
action of cytokines, like IL-2 and IL-15. Finally, the clonal LGL expansion does
not encounter a resolution for a third event establishing the activation
induced cell death (AICD) resistance, probably due to a genetic alteration.
All these events result in LGL aberrant outliving and number increase.
PBMCs, peripheral blood mononuclear cells; KIR, killer immunoglobulin-like
receptor; LGLs, large granular lymphocytes; DC, dendritic cell; AICD,
activation induced cell death; CLPD-NK, chronic lymphoproliferative disease
of natural killer cells.
It is believed that bone marrow, which is frequently involved
in CLPD-NK patients, represents the setting where the putative
inciting antigen could reside and dendritic cells (DCs) have been
suggested to represent the target of infection in these patients
(17). Interestingly, analysis of bone marrow biopsies of patients
demonstrated a topographic distribution of DCs and NK cells
that indicates a close contact between the two cell types (17). DCs
are also likely to represent the source of IL-15, which is crucial
in the mechanisms sustaining the maintenance of NK prolifer-
ation. IL-15 has been found to mediate its activity by altering
Bcl-2 family members, and more specifically by modulating Bid
expression (18).
ACTIVATING KIR AND VIRAL PROTECTION: IS IT TRUE IN
CLPD-NK?
Epidemiologic studies link activating KIR genes to resistance
against numerous virus infections (32). Beziat et al. showed that
infection with human CMV induce expansion and differentia-
tion of KIR-expressing NK cells, causing as stable imprints in
the repertoire (33). Interestingly, these authors showed that NK
education by inhibitory killer cell immunoglobulin-like receptors
(KIRs) was associated with a unique contribution of activating
KIRs (KIR2DS4, KIR2DS2, or KIR3DS1), in addition to NKG2C,
in the expansion of human NK cells. Interestingly,CMV-associated
factors have been suggested to specifically influence KIR gene
expression by regulating epigenetic expression of KIR genes (34).
In addition, in allogeneic bone marrow transplantation setting,
donor KIR2DS1 has been reported to protect against human CMV
reactivation (35). KIR3DS1 in conjunction with HLA-Bw4 with
an isoleucine at position 80 has been reported to be associated
with slower progression of HIV infection to AIDS (36). Pelac
et al. demonstrated that NK cells from individuals with mul-
tiple copies of KIR3DL1, in the presence of KIR3DS1 and the
appropriate ligands inhibit HIV-1 replication (37). This is fre-
quently associated with a significant expansion of KIR3DS1+,
but not KIR3DL1+, NK cells in HIV positive patients’ peripheral
blood. Epidemiological studies have indicated a protective effect
for the activating KIR2DS1 and KIR3DS1 genes also in patients
with EBV-associated Hodgkin’s lymphoma, although there is as
yet no direct evidence for the involvement of these receptors in
the recognition of EBV-transformed cells (38). KIR3DS1 genotype
has been shown to exert a positive effect on HCV viral clear-
ance during the first weeks of treatment in HCV/HIV infected
patients (39).
Although many of the above reported viral infections are at
least in part controlled by activating KIRs, a direct proof of the
role of these NK receptors in controlling a putative viral infection
in patients with CLPD is not available. This is likely due to the fact
that not a single, specific agent is responsible for the NK prolif-
eration, which perhaps represents the expression of an abnormal
processing of different foreign antigens.
ARE CLPD-NK CELLS LICENSED?
It is well known that NK functions are regulated by the integration
of signals received from activating and inhibitory receptors. To
prevent inadvertent activation against normal tissues, NK must be
educated to tolerate self, this process, termed “licensing,” acting
through an MHC-dependent mechanism requiring interaction
between inhibitory KIR and cognate MHC class I ligands (40).
Up to date, two models have been proposed to describe NK cell
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education (41): “arming” model and “disarming” model. In “arm-
ing” model, which is the best-known model proposed by Raulet
and Vance (42), NK cells acquire functional competence after
ligation of inhibitory receptors by self MHC class I molecules,
while NK cells lacking these inhibitory receptors for self MHC
enter in an “anergy” state. In this way, engagement of inhibitory
receptor by self MHC during NK cell maturation guarantees NK
cells to acquire “license to kill” and to become fully functional
competent.
Natural killer licensing involves not only inhibitory KIRs but
also activating KIRs have probably an underestimated role in this
process, which is complementary but with different outcome, since
it has been reported that education via activating KIRs decreases
NK cells response (43). However,“unlicensed”NK are not so“aner-
gic”but seem to have a crucial role in discrete settings. As an exam-
ple, in murine model, unlicensed NK cells were the main mediators
of NK cell-mediated control of mouse cytomegalovirus infection
in vivo. In fact, depletion of unlicensed NK cells impaired control
of viral titers, but depletion of licensed NK cells did not. Fur-
thermore, the transfer of unlicensed NK cells was more protective
than the transfer of licensed NK cells, indicating that unlicensed
NK cells are critical for protection against viral infection (44).
As stated above, in CLPD-NK, proliferating NK cells are char-
acterized by skewed KIR expression and selection and expansion
of NK subset expressing activating KIRs, instead of the more com-
mon NK cells expressing inhibitory KIRs, represent a crucial step in
the development of this disorder (10). Based on the recent insights
in NK cell education and function, in CLPD-NK, we can suppose
that expansion of long-lived NK cells involves “unlicensed” NK
equipped with activating KIRs, which have a predominant role
during viral infections, in accordance with the hypothesis that viral
stimulation may be the starting trigger of the disorder. According
with this suggestion, we performed HLA genotyping analysis in
29 CLPD-NK patients showing that in 93% of cases, a KIR/HLA-
I mismatch was present indicating that NK cell proliferation in
CLPD is mostly represented by unlicensed cells (21). Considering
that in healthy individuals, KIR/HLA-I genetic mismatch has been
detected in nearly 50% of cases, our results point to a role of the
KIR/HLA-I mismatch in the pathogenesis of the disease.
CONCLUSIVE REMARKS
Chronic lymphoproliferative disorders of NK cells are character-
ized by the expression of a restricted pattern of activating KIR
receptors on proliferating NK cells. It is believed from indirect
evidence that exogenous agent(s), likely of viral origin, might con-
tribute to the initial steps of disease. Recent knowledge on the
mechanisms of NK cell function and different contribution of NK
cell receptors against viral infections might help in the comprehen-
sion of the mechanisms leading to selection of a discrete NK cell
population. A possible inciting role of the putative antigen within
DCs in the bone marrow can be suggested. The inability of antigen
clearance and/or the occurrence of new events might contribute
to the persistence of NK clone. In this way, the identification that
STAT3 SH2 somatic mutations (45, 46), which can be found in
a fraction of CLPD-NK patients, might indicate that an acquired
genetic mutation could contribute to the immortalization of NK
proliferation.
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